MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 201-210

  Chen, Xiao Ping ^a,b   Chen, You Guo ^a   Lan, Jian Yun ^b   Shen, Zong Ji ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b YanCheng 1th People Hospital   (China)

Author keywords

Endoglin; Endometrioid ovarian cancer; MicroRNA; MiR 370; Target gene

Indexed keywords

CISPLATIN; ENDOGLIN; MICRORNA; MICRORNA 370; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MIRN370 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CLEAR CELL CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; DRUG RESISTANCE; DRUG SCREENING; ENDOMETRIOID OVARIAN CANCER; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIR-370; NUCLEOTIDE SEQUENCE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TARGET GENE; TUMOR CELL LINE; TUMOR VOLUME;

ENDOGLIN; ENDOMETRIOID OVARIAN CANCER; MICRORNA; MIR-370; TARGET GENE;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907555365     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.026     Document Type: Article

References (23)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin 2001, 51:15-36.
2. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol 2007, 14:195-208.
3. Ying H., Lv J., Ying T., Li J., Yang Q. Screening of feature genes of the ovarian cancer epithelia with DNA microarray. J. Ovarian Res 2013, 6:39.
4. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol 2010, 221:49-56.
5. Kuhn E., Kurman R.J., Vang R., Sehdev A.S., Han G., Soslow R., et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol 2011, 226:421-426.
6. Zhang S., Royer R., Li S., McLaughlin J.R., Rosen B., Risch H.A., et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol 2011, 121:353-357.
7. Moskwa P., Buffa F.M., Pan Y., Panchakshari R., Gottipati P., Muschel R.J., et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 2011, 41:210-220.
8. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
9. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J. Pathol 2011, 223:102-115.
10. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
11. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
12. Lee H., Park C.S., Deftereos G., Morihara J., Stern J.E., Hawes S.E., et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J. Surg. Oncol 2012, 10:174.
13. An F., Yamanaka S., Allen S., Roberts L.R., Gores G.J., Pawlik T.M., et al. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS ONE 2012, 7:e45606.
14. Zhang X., Zeng J., Zhou M., Li B., Zhang Y., Huang T., et al. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol. Cancer 2012, 11:56.
15. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33:e179.
16. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J. Biol. Chem 1999, 274:584-594.
17. Perez-Gomez E., Del Castillo G., Juan Francisco S., Lopez-Novoa J.M., Bernabeu C., Quintanilla M. The role of the TGF-beta coreceptor endoglin in cancer. ScientificWorldJournal 2010, 10:2367-2384.
18. Marioni G., Staffieri A., Manzato E., Ralli G., Lionello M., Giacomelli L., et al. A higher CD105-assessed microvessel density and worse prognosis in elderly patients with laryngeal carcinoma. Arch. Otolaryngol. Head Neck Surg 2011, 137:175-180.
19. Taskiran C., Erdem O., Onan A., Arisoy O., Acar A., Vural C., et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int. J. Gynecol. Cancer 2006, 16:1789-1793.
20. Steg A.D., Bevis K.S., Katre A.A., Ziebarth A., Dobbin Z.C., Alvarez R.D., et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res 2012, 18:869-881.
21. Ziebarth A.J., Nowsheen S., Steg A.D., Shah M.M., Katre A.A., Dobbin Z.C., et al. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin. Cancer Res 2013, 19:170-182.
22. Seitz H., Royo H., Bortolin M.L., Lin S.P., Ferguson-Smith A.C., Cavaille J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 2004, 14:1741-1748.
23. Royo H., Cavaille J. Non-coding RNAs in imprinted gene clusters. Biol. Cell 2008, 100:149-166.